309 related articles for article (PubMed ID: 22709619)
1. Pathological roles of purinergic signaling in the liver.
Vaughn BP; Robson SC; Burnstock G
J Hepatol; 2012 Oct; 57(4):916-20. PubMed ID: 22709619
[TBL] [Abstract][Full Text] [Related]
2. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
3. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.
Beldi G; Enjyoji K; Wu Y; Miller L; Banz Y; Sun X; Robson SC
Front Biosci; 2008 Jan; 13():2588-603. PubMed ID: 17981736
[TBL] [Abstract][Full Text] [Related]
4. Purinergic Signaling in Liver Pathophysiology.
Jain S; Jacobson KA
Front Endocrinol (Lausanne); 2021; 12():718429. PubMed ID: 34456873
[TBL] [Abstract][Full Text] [Related]
5. Extracellular ATP signaling and clinical relevance.
Dou L; Chen YF; Cowan PJ; Chen XP
Clin Immunol; 2018 Mar; 188():67-73. PubMed ID: 29274390
[TBL] [Abstract][Full Text] [Related]
6. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
7. The Role of Purinergic Signaling in Heart Transplantation.
Jiang Y; Lin J; Zheng H; Zhu P
Front Immunol; 2022; 13():826943. PubMed ID: 35529844
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
9. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
10. CD39-adenosinergic axis in renal pathophysiology and therapeutics.
Kishore BK; Robson SC; Dwyer KM
Purinergic Signal; 2018 Jun; 14(2):109-120. PubMed ID: 29332180
[TBL] [Abstract][Full Text] [Related]
11. Emerging Roles of Purinergic Signaling in Diabetes.
Fotino C; Dal Ben D; Adinolfi E
Med Chem; 2018; 14(5):428-438. PubMed ID: 29485002
[TBL] [Abstract][Full Text] [Related]
12. Purinergic Signaling During Immune Cell Trafficking.
Ferrari D; McNamee EN; Idzko M; Gambari R; Eltzschig HK
Trends Immunol; 2016 Jun; 37(6):399-411. PubMed ID: 27142306
[TBL] [Abstract][Full Text] [Related]
13. Purinergic signaling in hepatic disease.
Velázquez-Miranda E; Díaz-Muñoz M; Vázquez-Cuevas FG
Purinergic Signal; 2019 Dec; 15(4):477-489. PubMed ID: 31576486
[TBL] [Abstract][Full Text] [Related]
14. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
15. Purinergic signalling in the liver in health and disease.
Burnstock G; Vaughn B; Robson SC
Purinergic Signal; 2014 Mar; 10(1):51-70. PubMed ID: 24271096
[TBL] [Abstract][Full Text] [Related]
16. Extracellular nucleotide regulation and signaling in cardiac fibrosis.
Novitskaya T; Chepurko E; Covarrubias R; Novitskiy S; Ryzhov SV; Feoktistov I; Gumina RJ
J Mol Cell Cardiol; 2016 Apr; 93():47-56. PubMed ID: 26891859
[TBL] [Abstract][Full Text] [Related]
17. Ectonucleotidases in Intestinal and Hepatic Inflammation.
Vuerich M; Robson SC; Longhi MS
Front Immunol; 2019; 10():507. PubMed ID: 30941139
[TBL] [Abstract][Full Text] [Related]
18. [Purinergic signals].
Lazarowski ER; Schwarzbaum PJ
Medicina (B Aires); 2009; 69(2):267-76. PubMed ID: 19435702
[TBL] [Abstract][Full Text] [Related]
19. Cellular mechanisms of tissue fibrosis. 6. Purinergic signaling and response in fibroblasts and tissue fibrosis.
Lu D; Insel PA
Am J Physiol Cell Physiol; 2014 May; 306(9):C779-88. PubMed ID: 24352335
[TBL] [Abstract][Full Text] [Related]
20. Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.
Sun X; Han L; Seth P; Bian S; Li L; Csizmadia E; Junger WG; Schmelzle M; Usheva A; Tapper EB; Baffy G; Sukhatme VP; Wu Y; Robson SC
Hepatology; 2013 Jan; 57(1):205-16. PubMed ID: 22859060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
